Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 3
1979 4
1980 1
1984 3
1985 2
1986 5
1987 3
1988 3
1989 2
1990 7
1991 2
1992 3
1993 2
1995 1
1996 3
1997 1
2000 2
2001 2
2002 1
2003 1
2004 3
2005 3
2006 3
2007 1
2008 2
2009 4
2011 1
2012 4
2013 2
2014 3
2015 2
2016 2
2017 2
2018 1
2019 4
2020 3
2021 3
2022 3
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Kowdley KV, et al. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. N Engl J Med. 2024. PMID: 37962077 Clinical Trial.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Hirschfield GM, et al. Among authors: pratt ds. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. Hepatology. 2023. PMID: 37386786 Free PMC article. Clinical Trial.
Liver disorders.
Pratt DS. Pratt DS. Curr Opin Gastroenterol. 2008 May;24(3):265-8. doi: 10.1097/MOG.0b013e3282fbd371. Curr Opin Gastroenterol. 2008. PMID: 18408453 No abstract available.
In a tight spot.
Przybyszewski EM, Pratt DS. Przybyszewski EM, et al. Among authors: pratt ds. Clin Liver Dis (Hoboken). 2023 Apr 11;21(3):69-72. doi: 10.1097/CLD.0000000000000020. eCollection 2023 Mar. Clin Liver Dis (Hoboken). 2023. PMID: 37937257 Free PMC article.
Tamoxifen-induced steatohepatitis.
Pratt DS, Knox TA, Erban J. Pratt DS, et al. Ann Intern Med. 1995 Aug 1;123(3):236. doi: 10.7326/0003-4819-123-3-199508010-00018. Ann Intern Med. 1995. PMID: 7598311 No abstract available.
Implications of extended terminal sedation.
Sorum PC, Pratt DS. Sorum PC, et al. Among authors: pratt ds. J Med Ethics. 2023 Apr;49(4):265-266. doi: 10.1136/jme-2023-109019. Epub 2023 Feb 28. J Med Ethics. 2023. PMID: 36854626 No abstract available.
Seasonal influenza vaccination and technologies.
Nafziger AN, Pratt DS. Nafziger AN, et al. Among authors: pratt ds. J Clin Pharmacol. 2014 Jul;54(7):719-31. doi: 10.1002/jcph.299. Epub 2014 Apr 5. J Clin Pharmacol. 2014. PMID: 24691877 Review.
98 results